Andere talen Orphazyme A/S

Aandelen

Beurs gesloten - Nasdaq Copenhagen Andere beurzen 16:52:33 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.084 ^DKK	-1,45%		-0,97%	-18,51%

27/03	Orphazyme A/S rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
21/02	Orphazyme A/S (CPSE:ORPHA) verwierf een bijkomend onbekend minderheidsbelang in CombiGene AB (publ) (OM:COMBI).	CI

STALICLA Appoints Dr. Thomas Blaettler, MD	12/04
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
FDA Extends Review of Zevra's Arimoclomol by Three Months	04/03
BioStock: Comments from Orphazyme on the investment in CombiGene	04/03
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	21/02
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	21/02
Zevra Therapeutics Refiles Arimoclomol Application With FDA	27/12
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	10-10-23
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	28-09-23
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	12-09-23
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	12-09-23
Change in management	30-05-23
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	30-05-23
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO	30-05-23
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	30-05-23
Major shareholder announcement	19-05-23
Major shareholder announcement	17-05-23
Resolutions passed at the Annual General Meeting	17-05-23
Changes to the Board of Directors	17-05-23
Changes to the Board of Directors	17-05-23

Geen resultaten voor deze zoekopdracht